The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study)

BACKGROUND: Tiotropium + olodaterol has demonstrated improvements beyond lung function benefits in a large Phase III clinical program as a once-daily maintenance treatment for COPD and may be a potential option for the initiation of maintenance treatment in COPD. Despite guideline recommendations th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Chron Obstruct Pulmon Dis
Hlavní autoři: Beeh, Kai-Michael, Derom, Eric, Echave-Sustaeta, José, Grönke, Lars, Hamilton, Alan, Zhai, Dongmei, Bjermer, Leif
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4745834/
https://ncbi.nlm.nih.gov/pubmed/26893551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S95055
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky